Key Takeaways
- Resilient topline, margin under-recovery: Revenue grew 8.6% YoY (9.4% ex-Russia) in Q4, but EBITDA margin slipped to 15.4% as the quarterly lag-based pricing model failed to keep pace with unprecedented input cost inflation.
- Pricing model is broken for this cycle: The decades-old quarterly lag-based price recovery left a clear gap in a one-sided volatile environment, forcing management into urgent, aggressive, and now monthly pricing conversations with customers.
- China and Europe are the twin overhangs: China faces a sharp QoQ decline from COVID disruptions and input costs, while Europe’s personal care category shrank through the entire COVID wave; both are expected to recover, but timing is uncertain.
- Management refuses to call a margin bottom: Citing an "unbelievably unpredictable" environment and the shock of the Ukraine war after previously believing margins had bottomed, leadership explicitly declined any margin guidance.
- What to watch next quarter: The pace and success of monthly price increases in closing the cost gap, any stabilization in China post-COVID lockdowns, and whether Europe’s personal care category begins its promised bounce-back.
Pricing & Margin Dynamics
- The core problem: Input costs across polymers, aluminium, packaging, and freight saw unprecedented one-sided volatility and inflation, while EPL’s historical quarterly lag-based pricing model could not keep up, leaving a clear and persistent gap.
- Gross margin erosion split: Roughly half the erosion came from under-recovery of pricing, the other half from translation losses, with gross margin broadly around 50%.
- The fix is aggressive and continuous: Management is no longer taking "no" for an answer, shifting from periodic price conversations to a model where they go back to customers every month to renegotiate, and is stepping up pricing aggressiveness, particularly in India.
- Contracted vs non-contracted split: A significant half of volumes are contracted with pass-through clauses, meaning pricing moves with input costs in both directions; on the non-contracted half, there could historically be a lag and higher propensity to retain pricing when commodities soften, but management is not having that conversation yet.
- Long-term margin conviction: Management believes commodity prices will not stay elevated forever as more supply enters the market, and when that tempering happens, margins will "get back to where they were or even better."
- No margin guidance given: Leadership explicitly declined to provide any margin guidance, citing moving pieces: continuing commodity cost increases, COVID impact in China potentially affecting volume and fixed-cost absorption, and an environment that remains "unbelievably unpredictable."
Kripalu: "Last time we said that our margins are bottomed out and then the Ukraine war happened right and there was a concomitant set... I have to caveat this by saying that the environment just remains unbelievably unpredictable."
Regional & Category Performance
| Region / Category | Trend | Commentary |
|---|---|---|
| MSR (Middle East, South Asia, Africa) | ▲ Strong | Revenue grew 23.4% for the full year, the fastest of all regions. |
| Americas | ▲ Strong | Full-year revenue up 12.9%; personal care delivered double-digit growth in beauty, cosmetics, and pharma combined. Q4 exit margin improved to 15.7% vs the full-year average. |
| EAP (East Asia Pacific) | ▲ Solid | Full-year revenue grew 10.3%. |
| Europe | ▼ Weak | Full-year revenue declined 2.6% but grew 4.7% excluding Russia and hand sanitizer; Q4 grew 4.2% (7.3% adjusted). Personal care category shrank through the entire COVID wave, but management is optimistic about a bounce-back. |
| China (within EAP) | ▼ Sharp QoQ decline | Q4 hit by Chinese New Year impact worse than usual, huge input cost increases, and COVID starting to materially impact toward quarter-end. All operations remained running. |
| Oral Care | ▲ Steady | Grew 8% in Q4, 10.2% for the full year. |
| Personal Care | ▲ Faster than Oral | Grew 9.5% in Q4, 11.2% for the full year, despite significant COVID impact on the category in Europe. Sustained at 46% of revenue mix. |
- Inventory built as a buffer: Normally two months of inventory is carried, but FY2022’s material availability and price volatility led EPL to build inventory wherever there was opportunity, placing service levels over cost efficiency; normalization and reduction expected once conditions stabilize.
China Uncertainty
- Q4 was a triple hit: Chinese New Year made Q4 the smallest quarter seasonally but the impact was larger than usual, input cost inflation was severe, and COVID began materially disrupting operations and demand toward quarter-end.
- Operations stayed open: EPL’s own facilities never closed, though some customers did shut down.
- Near-term caution: Management has "a sense that the worst maybe behind us" for March and April, but hastened to caveat that they do not know for sure, and the short-term outlook for China remains challenging.
Kripalu: "We have a sense that the worst maybe behind us right as far as March and April is concerned but in this game I would hasten to caveat that by saying we do not know for sure..."
Strategic Initiatives & Sustainability
- Platina ramp-up expected: Volumes from the fully recyclable Platina tube are expected to grow exponentially in FY2023, with adoption across large customers like Colgate, P&G, Unilever, and GSK, as well as smaller players like Hela and Vicco.
- In-house cap manufacturing: Commenced in India, part of a broader cost-containment push that also includes scrap and waste reduction and organizational efficiency scrutiny.
- Sustainability recognition: Won the WorldStar Global Packaging Award in 2022, joined the Ellen MacArthur New Plastic Economy initiative, became a founding member of the India Plastics Pact, and published its second sustainability report.
- Brazil project on track: The new Brazil facility is up and running; capex deployment is imminent, with supplies ready in a few quarters. Revenue contribution will be nominal in FY2023, with material impact expected only in FY2024.
- Creative Stylo Packs: The acquisition strengthened customer position and provided new plastic tube capacity, and has been margin accretive, but remains too small to materially move total EPL numbers.
Management’s Stance on Disclosure
- Volume growth withheld: Management declined to disclose volume growth for Q4 or FY2022, reiterating its view that volume is not a good representation of topline performance and that it reports only revenue growth.
- Regional personal care bifurcation withheld: An analyst noted this data was previously provided but absent in recent quarters; management did not supply it, noting only that the personal care category sustained at 46% of revenue.
- Price increase quantum withheld: Management declined to give specifics on the size or effective dates of recent price increases, describing it as a continuous process with no simple explanation across different customers, regions, and rates.
- No margin guidance: Explicitly and repeatedly declined, with the CEO stating "We do not want to give any margin guidance okay to be very, very clear."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Platina volume ramp | Volumes to grow exponentially across large and small customers | FY2023 |
| Cost containment | Actions across every P&L line: in-house caps, scrap reduction, org efficiency | Ongoing |
| Pricing model shift | Move from periodic to monthly price conversations with customers | Already underway |
| Brazil revenue contribution | Material impact expected | FY2024 (nominal in FY2023) |
| Inventory normalization | Reduce inventories from elevated levels once conditions normalize | No date (conditions-dependent) |
| Long-term margin recovery | Margins to return to prior levels or better when commodity prices temper | No date (commodity cycle-dependent) |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| Revenue growth | 8.6%, 9.4% adjusted for Russia in the base |
| Oral care growth | 8% |
| Personal care growth | 9.5% |
| EBITDA margin | 15.4%, lower than 15.7% in Q3 FY22 |
| Europe revenue growth | 4.2%, 7.3% adjusted excluding Russia and hand sanitizer |
| Europe EBITDA margin | 11.9% |
| Americas EBITDA margin | 15.7% |
| FY22 revenue growth | 11%, 11.2% like-for-like excluding Russia, CSPL and hand sanitizer |
| FY22 oral care growth | 10.2% |
| FY22 personal care growth | 11.2% |
| FY22 MSR region growth | 23.4% |
| FY22 EAP region growth | 10.3% |
| FY22 Americas region growth | 12.9% |
| FY22 Europe revenue growth | -2.6%, 4.7% adjusted excluding Russia and hand sanitizer |
| FY22 EBITDA margin | 16.8%, a decline of 306 bps versus FY21 |
| FY22 net profit decline | 16%, net of one-offs PAT down 12.3% versus previous year |
| Gross margin | ~50% |
| Personal care revenue mix | 46% of composition, sustained over last three to four quarters |
| China revenue share | ~25% of topline |
| Creative acquisition investment | ₹168 cr, from internal accruals |